Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

NCT ID: NCT02563067

Last Updated: 2021-05-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 877 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-12-03
• Study Completion Date: 2019-08-02

Brief Summary

This study aimed to determine the efficacy and safety of QAW039 and QAW039 450 mg compared to placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the following two populations:

• patient with inadequately controlled severe asthma and high eosinophil counts (eosinophil count at Visit 1 ≥250 cells/ µl) (sub-population)
• patients with inadequately controlled severe asthma (overall study population) Inadequate control is defined as partly controlled or uncontrolled asthma (GINA 2016)

Detailed Description

This study used a randomized, multicenter, double-blind, placebo-controlled parallel-group design in which QAW039 (150 mg and 450 mg) or placebo was added to GINA steps 4 and 5 asthma therapy.

The study included:

• Screening period of up to 2 weeks to assess eligibility;
• Run-in period of approximately 2 weeks and a maximum of 6 weeks on placebo to collect baseline data for efficacy variables and compliance with the Electronic Peak Flow/ eDiary device. Upon completion of the run-in period, all patients who met the eligibility criteria were randomized to one of three treatments: QAW039 150 mg or QAW039 450 mg or placebo once daily in a ratio of 1:1:1.
• Treatment period of 52 weeks (assessment period for all Primary and Secondary Outcome Measures). Clinic visits were scheduled approximately 4 weeks after randomization and then at approximately 8-week intervals during the active-treatment period. Phone calls occurred at specified time points between visits occurring at 8-week intervals. Patients who had successfully completed 52 weeks of treatment in this study were offered an optional participation in a safety study (CQAW039A2315).
• Follow-up period of 4 weeks, investigational and drug-free, following the last dose of study drug. A follow-up visit occurred approximately 4 weeks (i.e., approximately 30 days) following the last dose of study therapy to complete safety assessments and pregnancy testing (if applicable).

The follow-up period applied to all patients except those patients who had entered the optional safety study (CQAW039A2315) directly after the Week 52 study visit

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

QAW039 150 mg

QAW039 150 mg once daily

Group Type: EXPERIMENTAL

QAW039

Intervention Type: DRUG

QAW039 150 mg once daily

QAW039 450 mg

QAW039 450 mg once daily

Group Type: EXPERIMENTAL

QAW039

Intervention Type: DRUG

QAW039 450 mg once daily

Placebo

Placebo once daily

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo once daily

Interventions

QAW039

QAW039 150 mg once daily

Intervention Type: DRUG

QAW039

QAW039 450 mg once daily

Intervention Type: DRUG

Placebo

Placebo once daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Written informed consent.
• Male and female patients aged ≥12 years.
• A diagnosis of severe asthma, uncontrolled on GINA 4/5 asthma medication.
• Evidence of airway reversibility or airway hyper- reactivity.
• FEV1 ≤80% of the predicted normal value for patients aged ≥18 years; FEV1 of ≤90% for patients aged 12 to <18 years
• An ACQ score ≥1.5
• A history of 2 or more asthma exacerbations within the 12 months prior to entering the study.

Exclusion Criteria

• Use of other investigational drugs within 5 half-lives of study entry, or within 30 days, whichever is longer.
• Subjects who have participated in another trial of QAW039.
• A QTcF (Fridericia) ≥450 msec (male) or ≥460 msec (female).
• History of malignancy with the exception of local basal cell carcinoma of the skin.
• Pregnant or nursing (lactating) women.
• Serious co-morbidities.
• Patients on >20 mg of simvastatin, > 40 mg of atorvastatin, >40 mg of pravastatin, or >2 mg of pitavastatin.

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Novartis Investigative Site

Little Rock, Arkansas, United States

Novartis Investigative Site

San Jose, California, United States

Novartis Investigative Site

Stockton, California, United States

Novartis Investigative Site

Colorado Springs, Colorado, United States

Novartis Investigative Site

Denver, Colorado, United States

Novartis Investigative Site

Winter Park, Florida, United States

Novartis Investigative Site

Overland Park, Kansas, United States

Novartis Investigative Site

Louisville, Kentucky, United States

Novartis Investigative Site

New York, New York, United States

Novartis Investigative Site

The Bronx, New York, United States

Novartis Investigative Site

Edmond, Oklahoma, United States

Novartis Investigative Site

Philadelphia, Pennsylvania, United States

Novartis Investigative Site

Greenville, South Carolina, United States

Novartis Investigative Site

Dallas, Texas, United States

Novartis Investigative Site

Houston, Texas, United States

Novartis Investigative Site

Plano, Texas, United States

Novartis Investigative Site

Richmond, Virginia, United States

Novartis Investigative Site

Richmond, Virginia, United States

Novartis Investigative Site

Berazategui, Buenos Aires, Argentina

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Novartis Investigative Site

Lanús, Buenos Aires, Argentina

Novartis Investigative Site

Mar del Plata, Buenos Aires, Argentina

Novartis Investigative Site

Ranelagh, Partido de Berazate, Buenos Aires, Argentina

Novartis Investigative Site

Buenos Aires, Ciudad Autonoma de Bs As, Argentina

Novartis Investigative Site

Santa Rosa, La Pampa Province, Argentina

Novartis Investigative Site

Santa Fe, Rosario, Argentina

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Novartis Investigative Site

San Miguel de Tucumán, Tucumán Province, Argentina

Novartis Investigative Site

Buenos Aires, , Argentina

Novartis Investigative Site

Buenos Aires, , Argentina

Novartis Investigative Site

Mendoza, , Argentina

Novartis Investigative Site

Mendoza, , Argentina

Novartis Investigative Site

Santa Fe, , Argentina

Novartis Investigative Site

Vancouver, British Columbia, Canada

Novartis Investigative Site

Vancouver BC, British Columbia, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Québec, , Canada

Novartis Investigative Site

Jindřichův Hradec, Czech Republic, Czechia

Novartis Investigative Site

Teplice, Czech Republic, Czechia

Novartis Investigative Site

Teplice, CZE, Czechia

Novartis Investigative Site

Brno, , Czechia

Novartis Investigative Site

Karlovy Vary, , Czechia

Novartis Investigative Site

Mladá Boleslav, , Czechia

Novartis Investigative Site

Plzen-Bory, , Czechia

Novartis Investigative Site

Athens, GR, Greece

Novartis Investigative Site

Thessaloniki, GR, Greece

Novartis Investigative Site

Athens, , Greece

Novartis Investigative Site

Athens, , Greece

Novartis Investigative Site

Ahmedabad, Gujarat, India

Novartis Investigative Site

Ahmedabad, Gujarat, India

Novartis Investigative Site

Bangalore, Karnataka, India

Novartis Investigative Site

Bangalore, Karnataka, India

Novartis Investigative Site

Nagpur, Maharashtra, India

Novartis Investigative Site

Pune, Maharashtra, India

Novartis Investigative Site

Jaipur, Rajasthan, India

Novartis Investigative Site

Jaipur, Rajasthan, India

Novartis Investigative Site

Coimbatore, Tamil Nadu, India

Novartis Investigative Site

Madurai, Tamil Nadu, India

Novartis Investigative Site

Hyderabad, Telangana, India

Novartis Investigative Site

Lucknow, Uttar Pradesh, India

Novartis Investigative Site

Haifa, , Israel

Novartis Investigative Site

Jerusalem, , Israel

Novartis Investigative Site

Jerusalem, , Israel

Novartis Investigative Site

Petah Tikva, , Israel

Novartis Investigative Site

Rehovot, , Israel

Novartis Investigative Site

Ancona, AN, Italy

Novartis Investigative Site

Acquaviva delle Fonti, BA, Italy

Novartis Investigative Site

Bari, BA, Italy

Novartis Investigative Site

Brescia, BS, Italy

Novartis Investigative Site

Catania, CT, Italy

Novartis Investigative Site

Catanzaro, CZ, Italy

Novartis Investigative Site

Cona, FE, Italy

Novartis Investigative Site

Foggia, FG, Italy

Novartis Investigative Site

Messina, ME, Italy

Novartis Investigative Site

Padua, PD, Italy

Novartis Investigative Site

Pisa, PI, Italy

Novartis Investigative Site

Roma, RM, Italy

Novartis Investigative Site

Cagliari, Sicily, Italy

Novartis Investigative Site

Siena, SI, Italy

Novartis Investigative Site

Torino, TO, Italy

Novartis Investigative Site

Legnago, VR, Italy

Novartis Investigative Site

Verona, VR, Italy

Novartis Investigative Site

Milan, , Italy

Novartis Investigative Site

Milan, , Italy

Novartis Investigative Site

Reggio Emilia, , Italy

Novartis Investigative Site

Salerno, , Italy

Novartis Investigative Site

Chikushino-shi, Fukuoka, Japan

Novartis Investigative Site

Fukuoka, Fukuoka, Japan

Novartis Investigative Site

Kasuga, Fukuoka, Japan

Novartis Investigative Site

Hiroshima, Hiroshima, Japan

Novartis Investigative Site

Naka-gun, Ibaraki, Japan

Novartis Investigative Site

Sakaidechō, Kagawa-ken, Japan

Novartis Investigative Site

Takamatsu, Kagawa-ken, Japan

Novartis Investigative Site

Kagoshima, Kagoshima-ken, Japan

Novartis Investigative Site

Yokohama, Kanagawa, Japan

Novartis Investigative Site

Kishiwada, Osaka, Japan

Novartis Investigative Site

Hamamatsu, Shizuoka, Japan

Novartis Investigative Site

Bunkyo Ku, Tokyo, Japan

Novartis Investigative Site

Chuo Ku, Tokyo, Japan

Novartis Investigative Site

Setagaya-Ku, Tokyo, Japan

Novartis Investigative Site

Shinagawa-ku, Tokyo, Japan

Novartis Investigative Site

Toshima Ku, Tokyo, Japan

Novartis Investigative Site

El Chouf, LBN, Lebanon

Novartis Investigative Site

Beirut, , Lebanon

Novartis Investigative Site

El Achrafiyé, , Lebanon

Novartis Investigative Site

Kota Bharu, Kelantan, Malaysia

Novartis Investigative Site

Kuantan, Pahang, Malaysia

Novartis Investigative Site

Taiping, Perak, Malaysia

Novartis Investigative Site

Batu Caves, , Malaysia

Novartis Investigative Site

Guadalajara, Jalisco, Mexico

Novartis Investigative Site

Guadalajara Jalisco, Jalisco, Mexico

Novartis Investigative Site

Zapopan, Jalisco, Mexico

Novartis Investigative Site

Amsterdam, , Netherlands

Novartis Investigative Site

Arnhem, , Netherlands

Novartis Investigative Site

Leeuwarden, , Netherlands

Novartis Investigative Site

Leiden, , Netherlands

Novartis Investigative Site

Izhevsk, , Russia

Novartis Investigative Site

Moscow, , Russia

Novartis Investigative Site

Moscow, , Russia

Novartis Investigative Site

Moscow, , Russia

Novartis Investigative Site

N.Novgorod, , Russia

Novartis Investigative Site

Novosibirsk, , Russia

Novartis Investigative Site

Saint Petersburg, , Russia

Novartis Investigative Site

Saint Petersburg, , Russia

Novartis Investigative Site

Sestroretsk, , Russia

Novartis Investigative Site

Stavropol, , Russia

Novartis Investigative Site

Yekaterinburg, , Russia

Novartis Investigative Site

Belgrade, , Serbia

Novartis Investigative Site

Belgrade, , Serbia

Novartis Investigative Site

Kragujevac, , Serbia

Novartis Investigative Site

Dúbravka, Bratislava Region, Slovakia

Novartis Investigative Site

Bardejov, Slovak Republic, Slovakia

Novartis Investigative Site

Bojnice, Slovak Republic, Slovakia

Novartis Investigative Site

Liptovský Hrádok, Slovak Republic, Slovakia

Novartis Investigative Site

Bratislava, , Slovakia

Novartis Investigative Site

Komárno, , Slovakia

Novartis Investigative Site

Košice, , Slovakia

Novartis Investigative Site

Levice, , Slovakia

Novartis Investigative Site

Spišská Nová Ves, , Slovakia

Novartis Investigative Site

Vyšné Hágy, , Slovakia

Novartis Investigative Site

Tygerberg, Cape Town, South Africa

Novartis Investigative Site

Mowbray, , South Africa

Novartis Investigative Site

Panorama, , South Africa

Novartis Investigative Site

Málaga, Andalusia, Spain

Novartis Investigative Site

Palma de Mallorca, Balearic Islands, Spain

Novartis Investigative Site

Jerez de la Frontera, Cadiz, Spain

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Sabadell, Catalonia, Spain

Novartis Investigative Site

Lugo, Galicia, Spain

Novartis Investigative Site

Girona, , Spain

Novartis Investigative Site

Guadalajara, , Spain

Novartis Investigative Site

Las Palmas de Gran Canaria, , Spain

Novartis Investigative Site

Madrid, , Spain

Novartis Investigative Site

Madrid, , Spain

Novartis Investigative Site

Santiago de Compostela, , Spain

Novartis Investigative Site

Zaragoza, , Spain

Novartis Investigative Site

Taichung, Taiwan ROC, Taiwan

Novartis Investigative Site

Taichung, , Taiwan

Novartis Investigative Site

Taichung, , Taiwan

Countries

United States; Argentina; Canada; Czechia; Greece; India; Israel; Italy; Japan; Lebanon; Malaysia; Mexico; Netherlands; Russia; Serbia; Slovakia; South Africa; Spain; Taiwan

References

Brightling CE, Gaga M, Inoue H, Li J, Maspero J, Wenzel S, Maitra S, Lawrence D, Brockhaus F, Lehmann T, Brindicci C, Knorr B, Bleecker ER. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir Med. 2021 Jan;9(1):43-56. doi: 10.1016/S2213-2600(20)30412-4. Epub 2020 Sep 24.

Reference Type: DERIVED

PMID: 32979986 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2015-003172-67

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CQAW039A2314

Identifier Type: -

Identifier Source: org_study_id